Últimas noticias sobre Vaccinex (OTC:VCNX) Bolsa

Vaccinex

Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.

Vaccinex Inc

Jefferies analyst Brent Thill maintains Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) with a Buy and raises the price target from $190 to $200.

News

Price Target

Analyst Ratings

ORCL

Jefferies Maintains Buy on Oracle, Raises Price Target to $200

Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) has outperformed the market over the past 15 years by 10.29% on an annualized basis producing an average annual return of 22.12%. Currently, Insulet has a market capitalization of $21.56 billion. 
Buying $100 In PODD: If an investor had bought $100 of PODD stock 15 years ago, it would be worth $2,028.81 today based on a price of $306.35 for PODD at the time of writing.
<h3>Insulet's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749483012_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

PODD

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Stephens &amp; Co. analyst Jim Salera reiterates Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) with a Equal-Weight and maintains $49 price target.

Reiteration

Stephens & Co. Reiterates Equal-Weight on Chipotle Mexican Grill, Maintains $49 Price Target

<a href="https://www.thecaptainslog.io/groupon-glp-1-office-racket/" title="https://www.thecaptainslog.io/groupon-glp-1-office-racket/">https://www.thecaptainslog.io/groupon-glp-1-office-racket/</a>

Short Sellers

GRPN

Watching Groupon; Shares Move Lower, Traders Circulate Article By The Captain's Log Titled "Groupon Has Become a GLP-1 Affiliate Marketing and Bootleg Microsoft Office Racket"

Wolfe Research analyst Steve Fleishman downgrades Edison Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EIX#NYSE">EIX</a>) from Outperform to Peer Perform.

Downgrades

Wolfe Research Downgrades Edison Intl to Peer Perform

Wolfe Research analyst Andrew Rosivach downgrades Equinix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>) from Outperform to Peer Perform.

EQIX

Wolfe Research Downgrades Equinix to Peer Perform

Events

Exclusives

MSOS

From Benzinga's Cannabis Capital Conference: C3 Industries CEO, Ankur Rugta Says It Is Very Hard To Do M&A Deals Right Now, Says Currently Institutional Equity Is Non-Existent In The Cannabis Sector

WIIM

UNFI

United Natural Foods shares are trading lower after the company reported unauthorized activity on certain IT systems.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>HC Wainwright &amp; Co. analyst Brandon Folkes initiated coverage on Heron Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) with a Buy rating and announced a price target of $6. Heron Therapeutics shares closed at $2.10 on Friday. <a href="https://www.benzinga.com/quote/hrtx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst John Todaro initiated coverage on eToro Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETOR#NASDAQ">ETOR</a>) with a Buy rating and announced a price target of $80. Etoro Group shares closed at $68.70 on Friday. <a href="https://www.benzinga.com/quote/etor/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Compass Point analyst Ed Engel initiated coverage on Antalpha Platform Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANTA#NASDAQ">ANTA</a>) with a Buy rating and announced a price target of $20. Antalpha Platform shares closed at $12.77 on Friday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Brandon Oglenski initiated coverage on Ryder System, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/R#NYSE">R</a>) with an Overweight rating and announced a price target of $190. Ryder System shares closed at $150.60 on Friday. <a href="https://www.benzinga.com/quote/R/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Lake Street analyst Ryan Meyers initiated coverage on Sky Harbour Group Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKYH#NYSE">SKYH</a>) with a Buy rating and announced a price target of $14. Sky Harbour shares closed at $9.80 on Friday. <a href="https://www.benzinga.com/quote/SKYH/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying Ryder stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/r/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="597" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09112046/image-118-1024x597.png" alt="" class="wp-image-943397" style="width:644px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09112046/image-118-1024x597.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09112046/image-118-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09112046/image-118-768x447.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09112046/image-118.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45811726/cramer-says-hes-not-going-to-really-want-to-do-a-lot-of-china-right-now">Cramer Says He&#8217;s &#8216;Not Going To Really Want To Do A Lot Of China Right Now&#8217;</a> </li>
</ul>
Photo via Shutterstock

Initiation

Markets

ANTA

ETOR

HRTX

SKYH

This Ryder System Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Sidoti &amp; Co. analyst John Franzreb downgrades AZZ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>) from Buy to Neutral and maintains the price target from $101 to $101.

Sidoti & Co. Downgrades AZZ to Neutral, Maintains Price Target to $101

While Axos Financial Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AX#NYSE">AX</a>) loan growth is likely to remain "impressive," the company's advisor services segment "is adding another leg to the growth story," according to Needham.
The Analyst: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5f22a54029cf490001b01b94/kyle-peterson">Analyst Kyle Peterson</a> maintained a Buy rating and price target of $88.
The Thesis: Axos Advisor Services, which had around $28 billion in assets under custody as of March 31, "is a hidden gem," Peterson said in the note.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Axos Advisor Services is the sixth largest RIA (registered investment advisor) custodian in the US. It has 212 RIAs who have more than $1 million in assets under custody.
"This business is ~12% of revenue, and we believe it is underappreciated, especially given the efforts to combine custody, clearing, and banking under one umbrella," the analyst wrote.
He further stated that Axos Financial is leveraging AI much more than its banking and fintech peers, and this is likely to emerge as a margin tailwind.
AX Price Action: Axos shares had risen by 0.64% to $72.01 at the time of publication on Monday.
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/insights/analyst-ratings/25/06/45834002/breaking-down-axos-financial-6-analysts-share-their-views">Breaking Down Axos Financial: 6 Analysts Share Their Views</a></li>
</ul>
Image: Shutterstock

Analyst Color

Axos Financial's Core Business Strong But This Segment 'Is A Hidden Gem,' Says Analyst

On June 5, 2025, United Natural Foods, Inc. (the "Company") became aware of unauthorized activity on certain of its Information Technology (IT) systems. The Company promptly activated its incident response plan and implemented containment measures, including proactively taking certain systems offline, which has temporarily impacted the Company's ability to fulfill and distribute customer orders. The incident has caused, and is expected to continue to cause, temporary disruptions to the Company's business operations. The Company is working actively to assess, mitigate, and remediate the incident with the assistance of third-party cybersecurity professionals and has notified law enforcement. Pursuant to its business continuity plans, the Company has implemented workarounds for certain operations in order to continue servicing its customers where possible. The Company is continuing to work to restore its systems to safely bring them back online.
 &nbsp;
The investigation to assess the impact and scope of the incident remains ongoing and is in its early stages.
 &nbsp;

Management

United Natural Foods Reports Cybersecurity Incident Discovered June 5, 2025, Forcing Systems Offline And Disrupting Order Fulfillment; Company Implements Containment Measures, Workarounds, And Engages Third-Party Experts As Investigation Continues

From Benzinga's Cannabis Capital Conference: Next Titan Capital Co-Founder, Jade Green Says Currently The Cannabis M&A Market Is Distressed

RBC Capital analyst Ashish Sabadra maintains Cintas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) with a Sector Perform and raises the price target from $215 to $240.

CTAS

RBC Capital Maintains Sector Perform on Cintas, Raises Price Target to $240

<a href="https://investor.regeneron.com/events/event-details/46th-annual-goldman-sachs-global-healthcare-conference" title="https://investor.regeneron.com/events/event-details/46th-annual-goldman-sachs-global-healthcare-conference">https://investor.regeneron.com/events/event-details/46th-annual-goldman-sachs-global-healthcare-conference</a>

Global

REGN

Watching Regeneron; At Goldman Sachs Conference, Exec Reportedly Says 23andMe Auction Process Was Recently Reopened And Is "Fairly Complicated"; Says Tariff Situation Currently Enacted Is Not "Material" To Business, But Sectoral Tariffs Could Have An Impact

Baker Hughes Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) announced on Monday that it will sell its Precision Sensors &amp; Instrumentation (PSI) unit to Crane Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CR#NYSE">CR</a>) for approximately <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45834576/baker-hughes-announces-sale-of-precision-sensors-instrumentation-product-line-to-crane-company" rel="noreferrer noopener">$1.15 billion in cash</a>. The move is part of Baker Hughes&#8217; broader strategy to streamline its portfolio and reallocate capital toward higher-return opportunities.
PSI, a division within Baker Hughes&#8217; Industrial &amp; Energy Technology segment, includes well-known brands such as Druck, Panametrics, and Reuter-Stokes. These brands specialize in sensor-based technologies for measuring pressure, flow, gas, moisture, and radiation.
The unit employs roughly 1,600 people worldwide, and the sale includes all associated assets, including intellectual property and infrastructure.
Also Read: <a target="_blank" href="https://www.benzinga.com/m-a/25/06/45724879/cactus-takes-majority-stake-in-baker-hughes-spc-for-global-reach" rel="noreferrer noopener">Cactus Takes Majority Stake In Baker Hughes&#8217; SPC For Global Reach</a>
Lorenzo Simonelli, Chairman and CEO of Baker Hughes, said the sale supports the company&#8217;s renewed focus on core areas like rotating equipment, asset performance management, flow control, and decarbonization. He noted that the divestiture enhances long-term value creation and bolsters the company&#8217;s balance sheet.
Crane Company pegged the net value of the deal at $1.06 billion after expected tax benefits, citing PSI&#8217;s projected 2025 <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45834589/crane-company-to-acquire-precision-sensors-instrumentation-from-baker-hughes-company" rel="noreferrer noopener">sales of $390 million</a> and adjusted EBITDA of $60 million.
Max H. Mitchell, Chairman and CEO of Crane, described PSI as &#8220;a perfect fit&#8221; for its Aerospace &amp; Electronics and Process Flow Technologies divisions.
Mitchell highlighted how the Druck brand will strengthen Crane&#8217;s aerospace pressure sensing capabilities while Reuter-Stokes will significantly expand its nuclear detection portfolio. Panametrics, he added, brings advanced flow and moisture measurement solutions that serve a wide range of industrial applications.
Crane expects the acquisition to deliver a 10% return on invested capital within five years, with sales growth projected between 4% and 6%, alongside strong operating leverage. The acquisition will be financed through a mix of cash and new debt, with closing anticipated by late 2025 or early 2026.
Investors may also track relevant ETFs such as the Industrial Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>) and the iShares U.S. Industrials ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYJ#NYSE">IYJ</a>).
Price Action: At the last check on Monday, CR shares were trading higher by 1.03% to $179.51, and BKR stock was up 0.11% at $37.94.
Read Next:
<a target="_blank" href="https://www.benzinga.com/markets/asia/25/06/45834491/tesla-china-sales-surge-in-may-as-new-model-y-juniper-exported-for-the-first-time-amid-us-china-trade-war" rel="noreferrer noopener">Tesla China Sales Surge In May As New Model Y Juniper Exported For The First Time Amid US-China Trade War</a>
Photo by hkhtt hj via Shutterstock

Asset Sales

iShares Trust Dow Jones US Industrial Sector Index Fund

Baker Hughes Sells Sensors Unit To Crane Company For $1.15 Billion

DA Davidson analyst Brian Holland maintains The Campbell's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) with a Neutral and lowers the price target from $39 to $34.

DA Davidson Maintains Neutral on The Campbell's, Lowers Price Target to $34

A 31-year-old Reddit user recently opened up about their financial situation in a <a href="https://www.reddit.com/r/Millennials/comments/1l4fttx/how_are_you_all_doing_financially/">post</a> that resonated with hundreds of others. Working temp jobs at $20 an hour and picking up a second job on weekends for $12 an hour, the original poster said they worry about the future and asked fellow millennials: &#8220;How are you all doing financially?&#8221;
<h2 class="wp-block-heading">For Many, It&#8217;s A Struggle To Stay Afloat</h2>
&#8220;I do worry a lot about my future,&#8221; the poster wrote. &#8220;I worry I&#8217;ll end up like those old folks at Walmart who stand in front of the store greeting people.&#8221;
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.</li>
</ul>
The person detailed their situation: $3,500 in a high-yield savings account, $20,000 in an old 401(k), <a href="https://www.benzinga.com/personal-finance/25/04/44656837/build-your-retirement-portfolio-while-saving-for-emergencies-a-roth-ira-can-double-as-an-emergency-fund-is-that-true">$5,000 in a Roth IRA</a>, and about $8,000 in debt split between student loans and credit cards. They live with their mom and contribute to the mortgage, which has about $45,000 left. &#8220;We&#8217;ll most likely be able to pay the house off in five years,&#8221; they added.
A lot of people could relate and shared similar stories of feeling stuck or worried.
&#8220;Pushing 40 and working a dead-end job for $16/hr,&#8221; one person replied. &#8220;I&#8217;ve got $1 in savings, ~$8 in checking, ~$90 past my $11.5k credit limit on my card with interest eating me alive.&#8221;
Another person summed up their situation like this: &#8220;<a href="https://www.benzinga.com/personal-finance/24/11/41703390/are-you-richer-or-poorer-than-your-peers-heres-a-look-at-the-average-net-worth-for-your-income">Poorer than many my age</a> &#8211; oldest millennial. I am resigned to the fact that this is it for me, that dream of travel, that luxury resort, having nice things, kids going to college with less or no debt just isn't possible for me anymore.&#8221;
Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
<h2 class="wp-block-heading">Some Are Doing OK, But It&#8217;s Still Tight</h2>
Others said they are doing better but still feel stretched. One 35-year-old shared: &#8220;Divorced, and make $34/hr. Rent a small 2-bed/1-bath apartment, no kids. Savings of $127k and $30k in my 401(k). Paid off the last of my debt last year&#8230; now just <a href="https://www.benzinga.com/personal-finance/management/25/06/45719338/grant-cardone-says-if-you-want-to-get-out-of-the-middle-class-you-need-to-quit-saving-money-buying-homes-or-borrowing-for-college">saving for a house</a>.&#8221;
One parent said they make $115,000 a year and own a home, but with kids and no second income, it&#8217;s &#8220;tight,&#8221; but they carry no debt other than mortgage and their needs are met.
<h2 class="wp-block-heading">High Earners Exist, But Acknowledge Luck</h2>
Some commenters reported strong finances, but many emphasized how rare and fragile that position feels. One couple, both in tech, said they make over $300,000 annually with $1.6 million in retirement savings and a nearly paid-off mortgage. &#8220;We&#8217;re very fortunate. Certainly didn&#8217;t plan on this,&#8221; they wrote.
A Redditor who <a href="https://www.benzinga.com/news/25/02/43850350/dave-ramsey-says-hes-going-to-be-miserable-if-when-a-wife-asks-if-her-husband-should-join-the-military-to-get-student-loans-forgiven">joined the military</a> right out of high school and did 8 years in the Navy shared: &#8220;I'm now a firefighter/paramedic making $100k a year and I also receive VA disability pay&#8230; We have about $200k in savings and I will get a pension when I retire.&#8221;
Even among high earners, there's a sense that things could turn quickly.&nbsp;
See Also: Wall Street's Missing This AI Surgical Tech — You Don't Have To.<a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution"> Invest from $350.</a>
<h2 class="wp-block-heading">One Crisis Away</h2>
Several people repeated that stability is an illusion. &#8220;We are okay but one crisis away from being really not okay,&#8221; one person shared.
As another reflected, &#8220;Every day I feel better about how I&#8217;m doing reading where other people are at. I really messed up in my early 20s. Ended up having a foreclosure and tens of thousands of dollars in credit card debt. I found Dave Ramsey, cleaned up my debt and did a &#8216;strategic foreclosure.'&#8221;
Despite wide-ranging experiences, the thread underscored a common feeling among many millennials: that even if you&#8217;re doing everything &#8220;right,&#8221; it&#8217;s still hard to feel secure.
Read Next: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>
Image: Shutterstock

Personal Finance

A Millennial Making $20 An Hour Says They Worry About Ending Up Like The Old Greeters At Walmart, Asks: 'How Are You All Doing Financially?'

Turmoil between SpaceX CEO Elon Musk and the White House puts space stocks in the spotlight. Here's a weekly round-up of recent highlights, news catalysts and upcoming events in the <a href="https://www.benzinga.com/news/space/25/06/45724938/space-stocks-weekly-countdown-rocketlab-gets-analyst-love-while-virgin-galactic-slides-into-june">space stock sector.&nbsp;</a>
What To Know: Last week, Musk and President Donald Trump began a <a href="https://www.benzinga.com/news/movers-shakers/25/06/45807280/elon-musk-bleeds-34-billion-as-tesla-shares-tank-14-amid-spat-with-trump-how-the-billionaires-fortune-has-fared-so-far-in-2025">public feud over</a> the "Big, Beautiful Bill" that quickly escalated to personal attacks. Trump openly suggested terminating federal contracts with Musk's companies like SpaceX. 
Read Next: <a href="https://www.benzinga.com/news/politics/25/06/45795080/whatever-you-think-of-elon-musk-you-must-support-his-fight-against-the-big-beautiful-bill-says-black-swan-author-nassim-taleb?utm_source=articleShare">&#8216;Whatever You Think Of Elon Musk, You Must Support His Fight Against The Big Beautiful Bill,&#8217; Says &#8216;Black Swan&#8217; Author Nassim Taleb</a>&nbsp;
Trump's threat sent space stocks higher as investors speculated that the feud between Trump and Musk could open new government <a href="https://www.benzinga.com/news/space/25/06/45805188/rocket-lab-ast-spacemobile-virgin-galactic-shares-are-rising-after-hours-whats-going-on">contract opportunities</a> for SpaceX competitors.&nbsp;
AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) jumped more than 35% last week and Virgin Galactic Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NYSE">SPCE</a>) shares rose 12% over the past five days, with both stocks trending again on Monday.&nbsp;
Shares of Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) took a backseat and dipped slightly on light trading volume Monday as investors focused their attention on other space stocks.&nbsp;
What Else: AST SpaceMobile shares also got a boost from a Scotiabank analyst<a href="https://www.benzinga.com/news/space/25/06/45776611/ast-spacemobile-stock-climbs-after-analyst-flags-potential-investment-from-amazons-jeff-bezos"> note last week</a> speculating that Amazon's Jeff Bezos could become an investor in the company.&nbsp;
Rocket Lab Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) postponed its next Electron launch for "The Mountain God Guards" mission due to weather, with the launch window now slated to open on Wednesday.&nbsp;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x2705; Another wet dress rehearsal complete for our next Electron launch. Due to weather, we're now targeting lift-off for June 11 UTC/June 12 NZT. &#x23f0; Launch timing: NET 15:15 UTC/03:15 NZT &#x1f680;Mission: ‘The Mountain God Guards' &#x1f3af;Customer: iQPS &#x1f6f0;&#xFE0F;Payload: QPS-SAR-11 &#x1f4cd;Launch Site:… <a href="https://t.co/71flsWhJIW">pic.twitter.com/71flsWhJIW</a>
&mdash; Rocket Lab (@RocketLab) <a href="https://twitter.com/RocketLab/status/1931922293334425788?ref_src=twsrc%5Etfw">June 9, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/social-media/25/06/45749596/the-viral-student-loan-solution-people-cant-stop-talking-about?utm_source=articleShare">The Viral Student Loan Solution People Can&#8217;t Stop Talking About</a></li>
</ul>
Image: Shutterstock

Equities

SPACE

Politics

Movers

Tech

General

ASTS

LUNR

RKLB

SPCE

Trump, Musk Feud Fuels SpaceX Rivals: Space Stock Countdown

Financing

Press Releases

Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross Proceeds

Health Care

Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference on October 31, 2024

Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain

Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting

Vaccinex Provides Update on ActivMAb® Platform:  Multiple Project Deals and Presentation at SITC

Earnings

Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Vaccinex Announces Receipt of Delisting Notification from Nasdaq

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

VCNX

Comments

Vaccinex

Noticias

Últimas noticias sobre Vaccinex (OTC:VCNX) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL